Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 06, 2025 8:40 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake†or the "Company†) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On September 28, 2025, MoonLake disclosed the 1 ...

Accessibility StatementSkip Navigation WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statemen ...

ROSEN, A LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 05, 2025 6:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), ...

Core Points - MoonLake Immunotherapeutics has announced an underwritten offering of 7,142,857 Class A ordinary shares at a price of $10.50 per share, aiming to raise approximately $75 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about November 6, 2025, pending customary closing conditions [1]. - Leerink Partners is acting as the sole bookrunning manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used alongside existing cash and marketable securities to fund the research and development of sonelokimab and for general corporate purposes [2]. Group 3: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody, targeting inflammatory diseases with significant unmet needs [5]. - The company addresses conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis, which affect millions globally [5].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39630 MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98-1711963 (State or o ...

The Company today also released new data from multiple clinical trials of its Nanobody SLK: ® MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the third qu ...

Core Insights - MoonLake Immunotherapeutics reported its financial results for Q3 2025, highlighting significant cash reserves and ongoing clinical trials for its investigational therapy sonelokimab [1][2]. Financial Performance - As of September 30, 2025, the company had cash, cash equivalents, and short-term marketable debt securities totaling $380.5 million, which is expected to fund operations into the second half of 2027 [2]. - Research and development expenses for Q3 2025 were $60.6 million, an increase from $49.8 million in the previous quarter, attributed to higher costs associated with clinical trials and consulting [2]. - General and administrative expenses remained stable at $10.8 million compared to $10.9 million in the previous quarter [2]. Clinical Trials and Data - New data from the Phase 2 LEDA trial indicated that sonelokimab (SLK) provided a 64% mean percent change in the Palmoplantar Psoriasis Area and Severity Index (PPPASI) at week 16, with 39% of patients achieving a ≥75% reduction [3]. - Interim analyses from the VELA-1 and VELA-2 Phase 3 trials in adult patients with Hidradenitis Suppurativa (HS) showed continuous clinical improvement beyond the primary endpoint at week 16 [4]. - The VELA-TEEN trial, focusing on adolescent HS patients, reported that 46% of participants achieved a HiSCR75 response at week 16 [5]. Regulatory and Future Milestones - A Type B meeting with the FDA is scheduled for December 15, 2025, to discuss the clinical evidence package for SLK in HS to support a Biologics License Application (BLA) [4][6]. - Upcoming milestones include the primary endpoint readout of the Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA) in Q1 2026 and the initiation of a Phase 3 trial in palmoplantar pustulosis (PPP) in Q3 2026 [6][8]. Market Context - Hidradenitis Suppurativa affects an estimated 2% of the population, with a projected market opportunity reaching $15 billion by 2035 due to the significant unmet need for effective treatments [24]. - The company is focused on inflammatory diseases with high unmet needs, including HS, psoriatic arthritis, and axial spondyloarthritis, which affect millions globally [10][14].